HCL-TECHNOLOGIES
HCL Technologies UK Limited, a wholly owned subsidiary of HCL Technologies (HCL), a leading global technology company, has signed a definitive agreement for the acquisition of Confinale AG, a Switzerland-based digital banking and wealth management consulting specialist and Avaloq Premium Implementation Partner. Through this strategic acquisition, HCL will increase its footprint in the global wealth management market with emphasis on Avaloq consulting, implementation and management capabilities.
Founded in 2012, Confinale focuses on IT consulting in key specialist areas in the banking and wealth management sector. Confinale has one of the largest independent pools of Avaloq-certified specialists in Europe and its in-house developed products and solutions accelerate the implementation of the Avaloq platform. Confinale is one of only four companies to be awarded the title of Avaloq Premium Implementation Partner. With offices in Switzerland including Zurich, Zug and Geneva; as well as Düsseldorf and London, Confinale works with a host of leading banks and wealth advisors.
The intellectual properties that are a part of this acquisition support HCL’s strategy to create specialized vertical domain capabilities and positions the company as a leader in end-to-end implementation and lifecycle management of the Avaloq platform. This builds upon HCL’s recently expanded global partnership with Avaloq and its acquisition of German IT consulting company gbs in association with apoBank in December 2021.
“Becoming part of HCL is an exciting new chapter for Confinale,” said Roland Staub, CEO, Confinale. “We strongly believe in the need for banking expertise combined with software competence and HCL is the perfect fit for this. It is a truly global player with strong heritage in the financial services sector. HCL’s reach will enable us to further our growth and at the same time expose our team to new learning and innovation opportunities.”
“There is significant disruption taking place in global wealth management and this means an opportunity for technology-led innovation,” said Rahul Singh, President of Financial Services and Digital Process Operations, HCL Technologies. “This acquisition significantly strengthens HCL’s digital wealth and asset management capabilities and expands our presence in the heart of the global investment banking sector. We welcome the team from Confinale and look forward to continuing to drive digital banking innovation alongside Avaloq.”
“At Avaloq we welcome the coming together of two of our key strategic partners,” said Martin Greweldinger, Co-Chief Executive Officer, Avaloq. “Both HCL and Confinale have considerable domain knowledge in financial services and deep understanding of our technology. We see the combination as immensely beneficial as Confinale has strong implementation credentials, including being awarded as best implementation partner in 2020 and 2021. We believe that this coming together will help accelerate digital wealth transformation for our clients and in turn increase the pace of adoption of Avaloq’s products and services globally.”
The acquisition is subject to customary closing conditions, which is expected to be completed in due course.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005383/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom